Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long‐term efficacy and safety of first‐line ibrutinib‐based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across...

Descripción completa

Detalles Bibliográficos
Autores principales: Allan, John N., Shanafelt, Tait, Wiestner, Adrian, Moreno, Carol, O’Brien, Susan M., Li, Jianling, Krigsfeld, Gabriel, Dean, James P., Ahn, Inhye E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy–Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299890/
https://www.ncbi.nlm.nih.gov/pubmed/34865212
http://dx.doi.org/10.1111/bjh.17984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299890/
https://www.ncbi.nlm.nih.gov/pubmed/34865212
http://dx.doi.org/10.1111/bjh.17984

Ejemplares similares